抗肿瘤靶向药物概论--赵军北京大学.pptVIP

易瑞沙抗肿瘤的近期疗效方面,我们可以看到客观缓解率一致地保持在15%-55%左右 Reference Park K, Goto K. A review of the benefit-risk profile of Gefitinib in Asian patients with advanced non-small-cell lung cancer. Current Medical Research and Opinions 2006; 22 (3): 561-573. 中国注册临床显示，易瑞沙的常见药物不良反应有皮疹,腹泻等 但大部分为CTC I-II级,不需处理;与研究药物相关或可能相关的CTC III-IV级不良事件共5例;未见发生明确的肺间质病变的病例 Reference 管忠震, 张力, 李龙芸等. 吉非替尼治疗局部晚期或转移性非小细胞肺癌在中国的临床研究. 癌症 2005; 24(8): 980-984. Advances in the treatment of non-squamous metastatic NSCLC have led to increasingly longer overall survival (OS). In the 1970s, OS with best supportive care was 2–5 months. OS improv